SUBSCRIBE
SUBSCRIBE

Phase II

Drug Development
Biogen Shares Positive Data on Phase I/II Trial of Tofersen for SOD1-ALS
Biogen announced on Wednesday that it has seen positive results from its Phase I/II study of tofersen, also known as BIIB067, for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).
July 10, 2020
 · 
3 min read
 · 
Krystle Vermes
Drug Development
Clinical Catch-Up: July 6-10
Everybody seems to be back to work after the U.S. 4th of July holiday. Here’s a look at last week’s clinical trial updates.
July 10, 2020
 · 
10 min read
 · 
Mark Terry
Drug Development
Low-Dose Radiation May Lower Inflammation in COVID-19 Patients
Low-dose radiation therapy seems to improve outcomes for COVID-19 patients. At least a dozen clinical trials are underway throughout the world to further explore the benefits.
July 9, 2020
 · 
5 min read
 · 
Gail Dutton
Policy
Biopharma Update on the Novel Coronavirus: July 10
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 10, 2020.
July 9, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
NIAID Creates Clinical Trials Network to Focus on COVID-19 Vaccines, Monoclonal Antibodies
The National Institute of Allergy & Infectious Diseases (NIAID) has founded a new clinical trials network focused on enrolling volunteers in clinical trials for COVID-19 vaccines and monoclonal antibodies.
July 9, 2020
 · 
3 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: July 8
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 8, 2020.
July 7, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: July 6
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 6, 2020.
July 6, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
Drug Development
Regeneron Launches Phase III COVID-19 Prevention Trial with Antibody Cocktail
Regeneron Pharmaceuticals, with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), is launching Phase III trials of REGN-COV2, the company’s two-antibody cocktail for the treatment and prevention of COVID-19.
July 6, 2020
 · 
3 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: July 3
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 3, 2020.
July 2, 2020
 · 
1 min read
 · 
BioSpace Editorial Staff
Drug Development
Clinical Catch-Up: June 29-July 3
Heading into the 4th of July holiday in the U.S., there was still a fair amount of clinical trial news last week. Here’s a look.
July 2, 2020
 · 
7 min read
 · 
Mark Terry
Load More
PRESS RELEASES
Drug Development
Hoth Therapeutics Announces Major Milestone of First Patient Dosed in Phase 2a Clinical Trial
July 25, 2023
 · 
4 min read
Drug Development
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts
July 25, 2023
 · 
13 min read
Drug Development
Stoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) & the SWALLOWTAIL OLE Study in Children & Adolescents with Dravet Syndrome
July 25, 2023
 · 
17 min read
Drug Development
Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601’s Phase 2 Friedreich’s Ataxia Trial and to Initiate Open Label Extension Trial
July 25, 2023
 · 
9 min read
Drug Development
RemeGen’s Telitacicept Shows Significant Promise in Phase II Trial for Primary Sjogren’s Syndrome: Findings Published in Prestigious Rheumatology Journal
July 25, 2023
 · 
4 min read
Drug Development
Foresee Pharmaceuticals Selected for Late-Breaking Oral Presentation on its Aderamastat Phase 2 Study Results at the European Respiratory Society (ERS) International Congress 2023
July 25, 2023
 · 
4 min read
Drug Development
Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV
July 24, 2023
 · 
12 min read
Drug Development
Clarity reaches 50% recruitment milestone for Phase II SABRE prostate cancer trial
July 24, 2023
 · 
6 min read
Drug Development
The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship Program – Phase II Clinical Testing of OATD-01 is Ready for Launch
July 24, 2023
 · 
6 min read
Drug Development
Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension
July 24, 2023
 · 
5 min read
Drug Development
Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers
July 24, 2023
 · 
7 min read
Drug Development
Eagle Pharmaceuticals Announces First Patient Randomized in Phase 2 Study Evaluating CAL02, a Novel First-in-Class Anti-Toxin Drug Candidate, in Severe Community-Acquired Bacterial Pneumonia (SCABP)
July 24, 2023
 · 
10 min read
Drug Development
Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023
July 24, 2023
 · 
2 min read
Drug Development
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Daxdilimab for the Treatment of Systemic Lupus Erythematosus (SLE) Did Not Meet Primary Endpoint
July 21, 2023
 · 
3 min read
Drug Development
SunHo Announces First Patient Dosed in Phase I/II Clinical Trial of a Potential First-in-class Immunocytokine IBB0979
July 21, 2023
 · 
2 min read
Drug Development
Stoke Therapeutics to Host Webinar to Present New Data from Patients Treated with STK-001 in the Phase 1/2a Studies
July 21, 2023
 · 
2 min read
Drug Development
ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
July 20, 2023
 · 
4 min read
Drug Development
Elucida Oncology Announces First Patient Dosed with ELU001 in Expansion Cohort of its Phase 1/2 Clinical Trial
July 20, 2023
 · 
3 min read
Drug Development
Sentynl Therapeutics Supports Phase 2 of Rady Children’s Institute for Genomic Medicine® BeginNGS™ Program to Identify Treatable Genetic Diseases in Newborns
July 20, 2023
 · 
3 min read
Drug Development
Perfuse Therapeutics Announces Initiation of Enrollment to Ph2a portion of the Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma
July 20, 2023
 · 
3 min read
Load More